Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning versus bedtime olmesartan/amlodipine for nocturnal blood pressure control in essential hypertension
ChiCTR2200059719Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olmesartan medoxomil + amlodipine in essential hypertension (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Reduction in average nocturnal systolic blood pressure and 24-hour diastolic blood pressure control rate. Started Jun 2022; status: recruiting.
02
Drugs
olmesartan medoxomil + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2200059719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059719.